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Abstract 
Background & Aims: Despite high risk behavior, 10-20% of HCV multiple exposed 
individuals remain uninfected (MEU), whilst the remainder become infected (MEI). We 
hypothesize that host factors play a role in HCV susceptibility. We aimed to identify 
polymorphisms in host genes that encode for proteins involved in viral entry; CD81, 
Scavenger receptor 1 (SR-1), Low-density lipoprotein receptor (LDL-R), Claudin-1 
(CLDN1), Occludin (OCLN) and Niemann-Pick C1–like 1 (NPC1L1).  
Methods: MEI and MEU from two observational cohorts were selected. From the MSM 
study of acute infection with HCV (MOSAIC), HIV-1 infected MEU cases (n=30) and HIV-1 
infected MEI controls (n=32) were selected based on reported high-risk behavior. From 
the Amsterdam Cohorts Studies (ACS) injecting drug users (IDU) cohort, MEU cases (n=40) 
and MEI controls (n=22) were selected who injected drugs for ≥2 years, in the nineties, when 
HCV incidence was high. Selected single nucleotide polymorphisms (SNPs) were determined 
by sequencing or SNP assays.  
Results: No associations were found for SNPs within genes coding for CD81, SR-1, Claudin-
1 or Occludin between the MEU and MEI individuals from either cohort. We did observe a 
significant association for rs688 within the LDL-R gene with HCV infection (OR:0.41 
p=0.001), however, LDL cholesterol levels did not vary between individuals carrying the 
differential SNPs. Additionally, a marginal significant effect was found for rs217434 and 
rs2072183 (OR: 2.07 p=0.032 and OR:1.76 p=0.039, respectively) within NPC1L1.  
Conclusions: Our results demonstrate that the rs688 SNP within the LDL-R gene associates 
with HCV susceptibility through mucosal as well as intravenous exposure.  
 
Keywords HCV; HIV-1; LDL-R; polymorphism; rs688; single nucleotide 
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Lay Summary 
Despite high risk behavior a proportion of HCV multiple exposed individuals remain 
uninfected and where host factors may play a role in HCV susceptibility. We aimed to 
identify whether genetic modifications in genes encoding for proteins that are known to be 
involved with viral entry associate with infection risk. We identified alterations in the gene 
coding for the Low-density lipoprotein receptor (LDL-R) associated with risk of infection. 
This was found in individuals exposed sexually or through intravenous drug use. Genetic 
alterations within the LDL-R gene can therefore provide individuals with a modest protection 
against HCV infection. 
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INTRODUCTION 
With 71 million people chronically infected and 399.000 deaths from HCV-related liver 
disease, hepatitis C virus (HCV) is a major global health burden.
1
 Risk factors for acquiring 
an HCV infection in developed countries are injecting drug use (IDU) and high risk sexual 
behavior among men having sex with men (MSM).
2
 However, some individuals remain 
uninfected despite high-risk behavior. Several studies have shown that from the high risk IDU 
ultimately 10-20% do not become infected with HCV, suggesting a biological reason why 
those multiple exposed uninfected (MEU) individuals are less prone to acquire HCV.
3–5
  A 
number of immune specific genotypes have been associated with risk of HCV transmission, 
how an individual spontaneously resolves their HCV infection or response to treatment
6–9
  It 
has been described that three single nucleotide polymorphisms (SNPs) within the promoter 
region of the C-type lectin receptor DC-SIGN have associated with the risk of HCV 
transmission, but only through sexual and not intravenous exposure.
10
 The SNPs identified 
were shown to result in down-regulation of receptor expression and the link provides an 
indication that the interaction of HCV with dendritic cells is important when considering 
mechanisms of viral transmission.  
 
Multiple host molecules are involved in the multi-step entry process of HCV into target cells. 
Hepatocyte surface receptors and co-receptors including Tetraspanin CD81, human scavenger 
receptor class B (SR-BI), Claudin-1 (CLDN-1) and Occludin (OCLN) are essential for HCV 
cell entry. In addition, LDL-receptor (LDL-R) and Niemann-Pick C1-like 1 (NPC1L1) are 
associated with capturing HCV and cell attachment. More recently, the NPC1L1 cholesterol 
absorption receptor was identified as an HCV entry factor.
11
 The aim of our study was to 
identify polymorphisms in host genes and their promoters that encode for proteins that 
modulate virus entry into cells; CD81, SR-BI, LDL-R, CLDN-1, OCLN and NPC1L1.  
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STUDY POPULATIN AND METHODS  
Study populations 
1. HIV-1 infected MSM with high risk sexual behavior 
Serum samples were collected from HIV-1 infected, Western European MSM (n=62) from the 
MSM Observational Study of Acute Infection with Hepatitis C (MOSAIC) cohort recruited 
from either the Academic Medical Center or the OLVG Oost hospital in Amsterdam, the 
Netherlands. Serum samples were studied from MEU individuals (n=30) and multiple 
exposed infected (MEI) (n=32). Risk behavior data was available from behavioral 
questionnaires collected at 6 month intervals and MOSAIC Risk scores were subsequently 
calculated.
12  
Participants were categorized as MEU or MEI, based on reported behavioral risk 
factors at inclusion or any of the follow up visits which we previously found to be associated 
with sexual transmission of HCV in this cohort 
13
. Behavior with increased risk of acquiring 
HCV infection was defined as having reported at either inclusion or any of the follow-up 
visits any of the following: no or inconsistent condom use and anal intercourse with an HCV-
infected sex partner; fisting; use of sex toys; rectal bleeding during or after sex; group sex.
14–
18
 The MOSAIC study was approved by the Institutional Review Board of the Academic 
Medical Center under assigned study numbers NL26485.018.09 and NL48572.018.14. 
Informed written consent was obtained from all study participants. 
 
2. IDU 
Serum samples of Western European individuals from the Amsterdam Cohort Studies (ACS) 
among IDU were selected. A total of 62 individuals were selected (40 MEU and 22 MEI), 
who started injecting before 1990, which was a period with high HCV incidence among drug 
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users (up to 27.5/100 person years in the 1980s). Participants injected for ≥2 years and either 
seroconverted for HCV (MEI) or remained HCV seronegative (MEU) during follow-up.  
 
The ACS is an open prospective cohort study that started in 1995 and investigates the 
epidemiology, the natural history and pathogenesis of HIV-1 infection and other blood-borne 
and/or sexually transmitted diseases, as well as the effects of interventions. ACS participants 
complete a standardized questionnaire about their health, risk behavior, and socio-
demographic situation every 4-6 months.
19,20
  Blood is drawn for laboratory testing and 
storage. The ACS study was approved by the Institutional Review Board of the Academic 
Medical Center at the University of Amsterdam and ethical committees/board of directors of 
each institute recruiting participants. The assigned study numbers are MEC 07/182 and MEC 
09/040. 
 
3. DNA isolation and genotyping 
SNPs were selected covering the array of HCV entry genes, with only those that had a minor 
allele frequency (MAF) score >0.05 being included. DNA was isolated from 200 µl serum 
with the QIAamp DNA blood mini kit according to the manufacturers protocol (Qiagen). The 
SNPs were determined for each sample by the appropriate SNP assay or by sequencing. SNP 
assay: The genotypes were assessed using the Ready-to-use hot start reaction mix for High 
Resolution Melting (HRM) curve analysis using the LightCycler® 480 (Roche) in a volume 
of 20 µl as follows: 10 µl HRM 2x master mix, 2 µl MgCl2 (25 mM), 0.4 µl α-casein, 0.18 µl 
Fwd primer (50 µM, Biolegio), 0.18 µl Rev primer (50 µM, Biolegio), 5.24 µl Baker water, 2 
µl DNA template. Amplification was performed under the following conditions: 50°C for 2 
min, denaturation at 95°C for 10 min, followed by 45 cycles at 95°C for 15s and 60°C for 15s, 
72°C for 20s, followed by a HRM protocol of 95°C for 1 min, 40°C for 1 min and an 
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acquisition step of 60°C for 45s.  Sequencing: PCR amplification was performed with a 
touchdown-PCR protocol with the following cycling conditions: denaturation at 95°C for 5 
min, followed by 5 cycles at 94°C for 30s, 61°C for 30s (-0.5°C every cycle) and 72°C for 45s 
followed by 32 cycles at 94°C for 30s, 60°C for 30s and 72°C for 45s and a final extension 
step at 72°C for 10 min. The amplicons were sequenced in both directions with the same 
primers using Big dye terminator according to manufacturer’s instructions (Applied 
Biosystems, Inc., Norwalk CT).  
 
4. Measurement of LDL cholesterol level 
The determination of the LDL serum levels was calculated using the Friedewald formula; 
LDL cholesterol = total cholesterol level- HDL cholesterol level- (0.45 x triglyceride level) 
mmol/L. Total cholesterol and HDL cholesterol determination were performed using the 
Cobas c702 (Roche diagnostics). 
 
5. Statistical analysis 
Univariable logistic regression analysis was used to estimate the odds ratio (OR) and 
corresponding 95% confidence interval and p-values between MEU and MEI using R 
software version 3.2.2.
21
  An additive genetic model was used with the minor allele as the 
coded allele. This model assumes a linear increase (b) in the ln-odds ratio for each additional 
coded allele an individual carries. The resulting odds ratio are thus e
b
 and e
2b
 for an individual 
carrying one or two copies of the coded allele vs. a person carrying null copies of the coded 
allele (i.e. homozygous for the non-coded allele). A (conservative) Bonferroni correction for 
multiple testing was applied by dividing the nominal significance threshold  by the number of 
SNPs in the study. Thus a  p value of <0.00185 (0.05/27) was considered significant. Markers 
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were removed when not in Hardy-Weinberg equilibrium in the controls (p < 0.0001) or when 
more than 10% of the samples were missing.  
 
RESULTS 
1 Association between HCV susceptibility and host SNP genotypes 
Participant characteristics are shown in Table 1. Individuals from the MSM exposed 
MOSAIC (n=62) and IDU exposed ACS (n=62) cohorts) were genotyped for 27 SNPs in four 
different genes known to be involved in HCV infection (No SNPs were selected in CD81 and 
OCLN). We investigated whether associations could be found between the selected SNPs and 
HCV infection susceptibility. SNP genotype frequencies were compared between cases (HCV 
infected or ever HCV infected, n=54) and high-risk controls (HCV uninfected n=70). A 
marginal significant effect was found for rs9869236 in CLDN1 (OR: 0.46 p=0.016) and in 
NPC1L1 rs217434 (in combined cohort but also in MOSAIC alone) and rs2072183 (OR: 2.07 
p=0.032 and OR: 1.76 p=0.039, respectively) but did not pass the Bonferroni test for multiple 
testing. We found the rs688 T variant in the LDL-R gene to be significantly associated with 
decreased HCV susceptibility (OR: 0.41 p=0.0001). When the cohorts were analyzed 
separately the same trend was observed. A significant effect was found in the MOSAIC 
cohort but not when corrected with Bonferroni (OR=0.37 p=0.0176) and the same trend, 
although not significant, was found in the ACS cohort (OR=0.22 p=0.09) (Table 2).  
 
2. No association between LDL-R SNP genotypes and cholesterol levels 
Since the rs688 genotype within the LDL receptor gene associates with protection from 
infection we tested whether serum LDL levels could be associated with HCV susceptibility or 
with rs688 genotype. We therefore selected participants from the MOSAIC cohort (n=34) 
from whom serum was available for measuring LDL levels. No statistical significant 
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differences were found in serum LDL levels for any of the genotypes compared (Fig. 1), nor 
was there a difference in serum LDL levels when HCV MEI were compared with MEU (data 
not shown).  
 
DISCUSSION 
We identified a SNP in the LDL-R gene to be associated with susceptibility to HCV infection 
where the rs688 T allele was found to be associated with decreased susceptibility to HCV 
infection. The LDL-R plays a role in HCV infection of human hepatocytes. In vitro studies 
have shown that the receptor is involved in the early stage of HCV infection.
22
 A study by 
Petit et al among 68 chronically infected patients found a significant association between 
HCV viral load and LDL-R expression levels, suggesting that LDL-R is involved in HCV 
infection and/or replication. We report for the first time an association between LDL-R rs688 
and HCV infection susceptibility.  
 
The rs688 LDL-R SNP is located within exon 12 and represents a silent codon mutation. 
However, this SNP has been shown to affect cholesterol levels and affect splicing of the 
mRNA resulting in a loss of functional surface expression levels of the receptor. Rs688 has 
also been associated with total plasma cholesterol levels, together with rs7412 and rs429358 
in APOE, rs646776 in CELSR2, rs1367117 in APOB, rs6756629 in ABCG5, rs662799 in 
APOA5, rs10889353 in DOCK7, rs2304130 in NCAN, rs3846662 in HMGCR, rs2275543 in 
ABCA1, rs7275 in SMARCA4. All these genes are involved in the cholesterol pathway.
23
 A 
study by Gao et al has previously analyzed the mechanism whereby the silent SNP rs688 
affects LDL-R expression and demonstrated that rs688 caused an increase in exon 12 
alternative splicing, which affects translation of LDL-R resulting in reduced full length 
functional LDL-R cell surface expression through introducing a premature stop codon and 
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triggering non-sense mediated decay (NMD).  The rs688 TT (minor variant) caused a 6% 
reduction in splicing efficiency compared to the CT or CC genotype (mRNA not significantly 
lower, however less for the TT genotype). They also looked at the SNP effect on full-length 
mRNA production and showed that there was reduced surface expression of LDL-R (21.8%), 
more LDL-R in the lysosome (25.7%) and reduced uptake of the receptor (24.3%). For these 
studies they utilized a plasmid containing the full LDL-R mRNA sequence with and without 
the SNP introduced. These experiments suggest that besides alternative splicing the rs688 
SNP influences LDL-R activity via impaired LDL-R recycling and/or PCSK9 binding.  
Since the rs688 LDL-R SNP affects the receptor surface expression level and LDL-R plays a 
role in HCV cell entry, we hypothesize that in people with the LDL-R rs688 T allele, HCV 
cell entry is impaired, reducing the risk of acquiring an HCV infection. However, this 
explanation may be too simplistic. A recent paper by Yamamoto et al demonstrated that LDL-
R and SR-B1 redundantly participate in HCV entry.
24
 When both genes are systematically 
knocked out there is a major decrease in HCV entry in comparison to the single knock out 
phenotypes. Entry in the double knock outs could be rescued by exogenous expression of SR-
B1, LDL-R and also VLDLR.  
 
Previously, it has been shown that LDL-R genotype correlates with LDL levels in serum 25–28  
As we hypothesized that serum LDL levels could contribute to HCV susceptibility, we 
compared LDL levels between MEU and MEI, and between the different LDL-R genotypes. 
However, we did not observe such an effect in the MOSAIC cohort. This could be due to the 
fact we are only able to test a small subset of individuals. However, this suggests that the 
protective effect of the LDL-R rs688 T allele in this population is not mediated through serum 
LDL levels. Further research is warranted to gain better insights into the mechanisms behind 
the rs688 SNP influencing HCV infection susceptibility and the interaction with other factors.  
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We observed a marginal effect for rs9869236 in CLDN1 and rs217434 and rs2072183 in 
NPC1L1 with HCV susceptibility. These SNPs show an association with HCV infection but 
do not pass the Bonferroni correction. However, the Bonferroni correction is rather strict and 
some have suggested that Bonferroni correction is not needed unless testing large number of 
SNPs. Our results suggest that genetic variability in CLDN1 and NPC1L1 may play a role in 
HCV infection susceptibility but this topic obviously requires further testing in larger cohorts.  
 
Here we report that the LDL-R rs688 T variant is enriched within MEU. This effect seems to 
be independent of the transmission route of the virus, which is either through mucosal or IDU 
exposure. The strong correlation identified using a relatively small number of well 
characterized individuals is highly supportive of a biological effect, however, this finding 
needs to be confirmed using larger numbers of individuals.    
 
ACKNOWLEDGEMENTS  
We would like to thank all ACS and MOSAIC participants as well as Margreet Bakker and 
Astrid Newsum for cohort management support. This work was conducted within the 
framework of the Amsterdam Cohort Studies on HIV infection and AIDS (Web site: 
www.amsterdamcohortstudies.org), a collaboration between the Public Health Service of 
Amsterdam, the Academic Medical Center of the University of Amsterdam, Sanquin Blood 
Supply Foundation, the University Medical Center Utrecht, and the Dutch HIV Monitoring 
Foundation. The MOSAIC cohort was supported by the "AIDS Fonds"(grant numbers 2008 
026 and 2013 037) and funding was provided from the European Community's Seventh 
Framework Programme [FP7-2007-2013] under grant agreement n°HEALTH-F3-2012-
305578. 
 Page 14 ; Steba et al 
 
REFERENCES 
1. World Health Organization Data and statistics. 2015 Available at: 
http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/data-and-
statistics.  
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 
2007;13:2436–2441. 
3. Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M. Modelling the 
force of infection for hepatitis B and hepatitis C in injecting drug users in England and 
Wales. BMC Infect. Dis. 2006;6:93. 
4. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of 
hepatitis C virus infection in relation to time since onset of illicit drug injection: the 
influence of time and place. Am J Epidemiol. 2008;168:1099–1109. 
5. Thomas DL, Vlahov D, Solomon L,  et al. Correlates of hepatitis C virus infections 
among injection drug users. Medicine. 1995:74:212–220. 
6. Suppiah, V, Moldovan M, Ahlenstied G, et al. IL28B is associated with response to chronic 
hepatitis C interferon-alpha and ribavirin therapy. Nat  Genet. 2009;41:1100–1104. 
7. Ge, DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C 
treatment-induced viral clearance. Nature. 2009;461:399–401. 
8. Thio  C, Thomas DL, Goedert JJ,  et al. Racial Differences in HLA Class II 
Associations with Hepatitis C Virus Outcomes. J Infect Dis. 2001;184:16–21. 
9. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. 
Association between HLA class II genotype and spontaneous clearance of hepatitis C 
viraemia. J  Hepatol. 1998;29:207–213. 
10. Steba GS, Koekkoek SM, Vanhommerig JW, et al. DC-SIGN Polymorphisms 
Associate with Risk of Hepatitis C Virus Infection Among Men who Have Sex with 
 Page 15 ; Steba et al 
 
Men but not Among Injecting Drug Users. J. Infect. Dis. 2017;3:353-357.  
11. Sainz B, Barretto N, MArtin DN, et al. Identification of the Niemann-Pick C1-like 1 
cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 
2012;18:281–285. 
12. Newsum AM, Stolte IG, van der Meer JT, et al. Development and validation of the 
HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection 
in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22:1–9. 
13. Vanhommerig JW, Lambers FAE, Scinkel, et al. Risk Factors for Sexual Transmission 
of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have 
Sex With Men: A Case-Control Study. Open Forum Infect Dis. 2013;2:Issue3. 
14. Mahony AA, Donnan EJ, Lester RA, et al. Beyond injecting drug use : investigation of 
a Victorian cluster of hepatitis C among HIV-infected men who have sex with men. 
Med J Aust. 2013;198:210–214. 
15. Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute 
hepatitis C among HIV-positive gay men from Germany--a case-control study. PLoS 
One. 2011;6:e17781. 
16. Larsen C, Chaix ML, Le Strat Y, et al. Gaining greater insight into HCV emergence in 
HIV-infected men who have sex with men: the HEPAIG Study. PLoS One 
2011;6:e29322. 
17. Terrault NA. Sexual activity as a risk factor for hepatitis C Hepatology. 2002;36:S99-105. 
18. Garg S, Taylor LE, Grasso C, MayerKH, Prevalent and incident hepatitis C virus 
infection among HIV-infected men who have sex with men engaged in primary care in 
a Boston community health center. Clin Infect Dis. 2013;56:1480–1487. 
19. van Griensven GJP, Tielman RAP, Goudsmit J, et al. Risk factors and prevalence of 
HIV antibodies in homosexual men in the Netherlands. Am  J  Epidemiol. 
 Page 16 ; Steba et al 
 
1987;125:1048–1057. 
20. van den Hoek JA, CoutinhoRA, van Haastrecht HJ, van Zadelhoff AW, Goudsmit, J, 
Prevalence and risk factors of HIV infections among drug users and drug-using 
prostitutes in Amsterdam. AIDS. 1988;2:55–60. 
21. R Core team. R: A Language and Environment for Statistical Computing. 2013. 
22. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays 
a role in the infection of primary human hepatocytes by hepatitis C virus. J  Hepatol. 
2007;46:411–419. 
23. Lu Y, Feskems EJ, Boer JM, et al. Exploring genetic determinants of plasma total 
cholesterol levels and their predictive value in a longitudinal study. Atherosclerosis. 
2010;213:200–205. 
24. Yamamoto S, Fukuhara T, Ono, et al. Lipoprotein Receptors Redundantly Participate 
in Entry of Hepatitis C Virus. PLOS Pathog. 2016;12:e1005610. 
25. Gao F, Ihn HE, Medina MW, Krauss RM, A common polymorphism in the LDL 
receptor gene has multiple effects on LDL receptor function. Hum Mol Genet. 
2013;22:1424–1431. 
26. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population 
relevance of 95 loci for blood lipids. Nature. 2010;466:707-713.  
27. Boright AP, Connelly PW, Brunt JH, Morgan K, Hegele RA. Association and linkage 
of LDLR gene variation with variation in plasma low density lipoprotein cholesterol. J 
Hum Genet. 1998;43:153–159. 
28. Zhu H, Tucker HM, Grear KE, et al. A common polymorphism decreases low-density 
lipoprotein receptor exon 12 splicing efficiency and associates with increased 
cholesterol. Hum Mol Genet. 2007;16:1765-1772. 
 
 Page 17 ; Steba et al 
 
  
Table 1 
 
MOSAIC ACS 
Characteristics MEI MEU MEI MEU 
n (total=124) 32 30 22 40 
Mean age ± SD 43.0 ±6.9 48.5 ±7.9 52.0 ±6.9 52.8 ±7.2 
% Male gender 32 (100%) 30 (100%) 11 (50%) 29 (72.5%) 
% Dutch Nationality 28 (87.5%) 29 (96.7%) 19 (86.4%) 37 (92.5%)  
% HIV positive at entry 32 (100%) 30 (100%) 0 (0%) 0 (0%) 
HIV seroconversion during follow-up n.a n.a 3 (13.6%) 0 (0%)  
Median start date of Follow-up (IQR) 
22/2/2011 
(4/2/2010-
2/8/2011) 
14/2/2011 
(19/5/2010-
20/12/2011) 
23/2/1988 
(15/1/1987-
08/02/1992) 
20/10/1992 
(12/09/1988-
22/04/1998) 
Median time of follow-up ± SD 4.01 ± 1.80 3.78 ± 1.30 14.96 ± 5.65 14.31 ±5.62 
Mean duration IDU in years 
4 IDU in last 6 
months (no 
duration) 
n.a 7.21 ±3.42 8.45±4.83 
% Reported sharing of needles
§
 0 (0%) 0 (0%) 15(75%) 22 (55%) 
Having an HCV-infected sex partner* 7 (21.9%) 1 (3.3%) n.a n.a 
Fisting
§
 
    
With steady partner 9 (28.1%) 5 (16.7%) n/a n/a 
With casual partner(s) 10 (31.3%) 8 (26.7%) n/a n/a 
Use of sex toys
§
 
    
With steady partner 13 (40.6%) 12 (40%) n/a n/a 
With casual partner(s) 15 (46.9%) 4 (13.3%) n/a n/a 
Rectal bleeding during or after sex
§
 
    
With steady partner ` 10 (33.3%) n/a n/a 
With casual partner(s) 15 (46.9%) 8 (26.7%) n/a n/a 
Groupsex
§
 24 (75%) 23 76.7%) n/a n/a 
Rectal bleeding during or after sex* 17 (53.1%) 5 (16.7%)   
CD4 count last negative 
moment(cases)/last visit (controls)* 
523±138 621±222 n.a n.a 
CD4 count nadir 277±160 269±179 n.a n.a 
Baseline Mosaic Risk score (medium)*
#
  2,9  1,1     
 
n.a. = not applicable,  
* = p < 0,05   
§ 
reported at least once 
#
 [10] 
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 Table 2        Combined cohorts MOSAIC ACS 
Gene SNP Major allele Minor allele MAF
# 
MEU MAF
# 
 MEI OR
#
 95% CI
#
 p-value MAF
 
MEU MAF MEI OR 95% CI p-value MAF
 
MEU MAF MEI OR 95% CI p-value 
CLDN1 
rs8298 C T 0,343 0,439 1,41 0,86 to 2,32 0,176 0,362 0,452 1,32 0,7 to 2,49 0,3914 0,329 0,417 1,47 0,64 to 3,37 0,3659 
rs8798 G A 0,358 0,449 1,37 0,84 to 2,23 0,2059 0,362 0,452 1,32 0,7 to 2,49 0,3914 0,355 0,444 1,43 0,65 to 3,15 0,3805 
rs1060679 C T 0,152 0,083 0,55 0,25 to 1,21 0,1368 0,183 0,063 0,43 0,15 to 1,21 0,1089 0,128 0,114 0,85 0,25 to 2,92 0,7998 
rs17500920 T A 0,123 0,111 0,9 0,42 to 1,9 0,7813 0,117 0,141 1,18 0,46 to 3,01 0,726 0,128 0,068 0,46 0,11 to 1,88 0,2789 
rs9842576 G A 0,383 0,480 1,34 0,85 to 2,13 0,2107 0,308 0,450 1,57 0,8 to 3,1 0,1893 0,434 0,526 1,32 0,67 to 2,61 0,4219 
rs55724972 C A 0,109 0,102 0,94 0,45 to 1,98 0,8786 0,115 0,133 1,13 0,43 to 3 0,8053 0,105 0,053 0,56 0,14 to 2,35 0,4305 
rs1043747 A C 0,383 0,480 1,35 0,85 to 2,16 0,2046 0,269 0,450 1,83 0,9 to 3,7 0,0932 0,461 0,526 1,23 0,61 to 2,47 0,5561 
rs3172404 G A 0,185 0,200 1,08 0,61 to 1,91 0,7985 0,241 0,150 0,66 0,3 to 1,47 0,3121 0,145 0,275 1,96 0,82 to 4,72 0,1327 
rs9869263 G A 0,307 0,167 0,46 0,25 to 0,87 0,0159 0,183 0,109 0,57 0,21 to 1,55 0,2704 0,400 0,250 0,48 0,2 to 1,13 0,0938 
rs9848283 A G 0,400 0,472 1,29 0,8 to 2,07 0,2921 0,350 0,453 1,39 0,74 to 2,61 0,3126 0,438 0,500 1,29 0,61 to 2,71 0,5038 
rs17429833 G C 0,107 0,065 0,58 0,23 to 1,48 0,2512 0,117 0,047 0,41 0,1 to 1,6 0,198 0,100 0,091 0,89 0,23 to 3,37 0,8624 
rs12696600 A C 0,471 0,519 1,17 0,74 to 1,86 0,5021 0,417 0,484 1,22 0,66 to 2,25 0,5248 0,513 0,568 1,24 0,6 to 2,59 0,5584 
NPC1L1 
rs217434 T C 0,150 0,259 2,07 1,07 to 4,03 0,0315 0,083 0,281 5,51 1,72 to 17,7 0,0041 0,200 0,227 1,17 0,48 to 2,83 0,7249 
rs10264715 C T 0,093 0,130 1,43 0,65 to 3,15 0,3699 0,017 0,141 8,78 1,06 to 72,92 0,0443 0,150 0,114 0,72 0,23 to 2,23 0,5704 
rs2072183 C G 0,214 0,343 1,76 1,03 to 3,01 0,0392 0,183 0,344 1,95 0,92 to 4,15 0,0832 0,238 0,341 1,65 0,73 to 3,71 0,2282 
rs41279633 C A 0,157 0,250 1,59 0,9 to 2,81 0,1096 0,033 0,250 6,66 1,49 to 29,81 0,0132 0,250 0,250 1 0,46 to 2,18 1 
rs17655652 A G 0,321 0,231 0,66 0,38 to 1,14 0,137 0,383 0,266 0,63 0,31 to 1,28 0,203 0,275 0,182 0,57 0,22 to 1,46 0,2379 
SR-B1 
rs5888 C T 0,443 0,426 0,94 0,57 to 1,54 0,7946 0,450 0,422 0,9 0,45 to 1,78 0,7616 0,438 0,432 0,98 0,47 to 2,04 0,9517 
rs4238001 C T 0,100 0,094 0,95 0,44 to 2,03 0,8951 0,067 0,097 1,44 0,41 to 5,01 0,5713 0,125 0,091 0,77 0,27 to 2,22 0,624 
LDL-R 
rs1799898 T C 0,214 0,213 0,99 0,48 to 2,03 0,9764 0,183 0,234 1,52 0,55 to 4,21 0,4166 0,238 0,182 0,63 0,22 to 1,84 0,3989 
rs688 C T 0,550 0,324 0,41 0,24 to 0,7 0,001 0,417 0,203 0,37 0,16 to 0,84 0,0176 0,650 0,500 0,5 0,22 to 1,13 0,0972 
rs5927 G A 0,471 0,389 0,64 0,35 to 1,16 0,1374 0,533 0,422 0,59 0,27 to 1,29 0,1876 0,425 0,341 0,56 0,21 to 1,5 0,2475 
rs2738464 C G 0,129 0,130 1,01 0,53 to 1,92 0,9831 0,150 0,109 0,77 0,32 to 1,89 0,5743 0,113 0,159 1,37 0,53 to 3,51 0,5161 
rs2738465 G A 0,279 0,287 1,04 0,62 to 1,74 0,8917 0,233 0,281 1,24 0,58 to 2,64 0,572 0,313 0,295 0,93 0,44 to 1,96 0,8552 
rs1433099 G A 0,224 0,250 1,13 0,65 to 1,96 0,6727 0,259 0,200 0,77 0,36 to 1,66 0,5046 0,197 0,325 1,8 0,79 to 4,13 0,1623 
rs2738466 A G 0,182 0,260 1,5 0,83 to 2,72 0,1776 0,183 0,234 1,35 0,57 to 3,22 0,4928 0,181 0,300 1,73 0,75 to 3,96 0,1966 
rs17242683 G A 0,189 0,275 1,5 0,85 to 2,65 0,1619 0,200 0,258 1,33 0,6 to 2,94 0,4819 0,181 0,300 1,73 0,75 to 3,96 0,1966 
# MAF = minor allele frequency OR= Odds ratio calculated by dividing frequencies major allele over minor allele CI= confidence interval 
                   
*Statistically significant (P=<0.05) 
                  ** Passed Bonferroni test for multiple testing (P=<0.00185) 
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Figure 1 
 
 
Figure 1 Serum LDL levels were determined for 34 individuals from whom serum was available. A. Average serum levels shown per genotype; 
CC (n=14), CT (n=10) or TT (n=5). No significant difference in LDL levels and LDL-R rs688 genotype were found. B. No significant difference 
in LDL levels and LDL-R rs688 genotype were found when comparing the CC + CT (n=24) genotype with the TT (n=5) genotype. 
 
 
 Page 20 ; Steba et al 
 
Table and Figure Legends: 
 
Table 1 Characteristics of MOSAIC and ACS multiple exposed uninfected (MEU) and multiple exposed infected (MEI) participants.  
 
Table 2 Genotyping results of both the individual cohorts and combined. The most common allele was considered the major allele. An additive 
genetic model was used to determine the Odds ratio (OR) for the SNPs between multiple exposed uninfected (MEU) and multiple exposed 
infected (MEI) individuals in relation to infection susceptibility. Rs688 appears to be significantly associated with HCV infection and passed the 
Bonferroni test for multiple testing when the data of the MOSAIC and ACS cohort are combined. The minor rs688 T allele is more abundant in 
controls, hence the odds ratio of 0.41 suggests a protective effect of the T allele. 
 
 
